Pharmacokinetics of Low‐Dose Intravenous Pethidine in Patients with Renal Dysfunction

Authors:

Abstract
The kinetics and elimination of pethidine (meperidine) after intravenous administration (150 μg/kg) to ten healthy volunteer subjects were compared with those obtained from 18 patients who suffered from varying degrees of renal dysfunction. In both groups of subjects, pethidine was eliminated triexponentially from plasma. However, plasma concentrations in the patients (who were subdivided into patients with severe dysfunction, moderate dysfunction, and mild dysfunction) were consistently higher. The mean ± SEM elimination half‐life (t1/2) of pethidine was significantly longer in the three groups of renal patients: 7.9 ± 1.1, 20.2 ± 13.6, 16.6 ± 5.4, and 14.3 ± 3.1 hr, respectively, for healthy volunteers, patients with severe, moderate, and mild dysfunction; their mean ± SEM creatinine clearances were 97.3 ± 7.5, 1/2 of pethidine in renal patients may be attributable to a more extensive distribution of pethidine in the body (with a decrease in plasma protein binding) and a lower plasma clearance of the drugs.

This publication has 10 references indexed in Scilit: